Therapies targeting the inhibitory checkpoints CTLA-4 and PD-1 axis induce prominent anti-tumor responses and lasting clinical benefit in patients with different tumor types, including non-small cell lung cancer (NSCLC). Here, CTLA4 is linked to neoplasm.